Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tyler Risom

Showing results (21-30 of 30) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 30 results.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 5, 2013
Targeting activated Akt with GDC-0068, a novel selective Akt inhibitor that is efficacious in multiple tumor modelsJie Lin, Deepak Sampath, Michelle A Nannini, et al.
Bioorganic & Medicinal Chemistry Letters|October 26, 2010
Discovery of dihydrothieno- and dihydrofuropyrimidines as potent pan Akt inhibitorsJosef R Bencsik, Dengming Xiao, James F Blake, et al.
Nature Communications|September 21, 2018
Differentiation-state plasticity is a targetable resistance mechanism in basal-like breast cancerTyler Risom, Ellen M Langer, Margaret P Chapman, et al.
Nature Biotechnology|November 19, 2021
Whole-cell segmentation of tissue images with human-level performance using large-scale data annotation and deep learningNoah F Greenwald, Geneva Miller, Erick Moen, et al.
Cell|January 22, 2022
Transition to invasive breast cancer is associated with progressive changes in the structure and composition of tumor stromaTyler Risom, David R Glass, Inna Averbukh, et al.
ACS Medicinal Chemistry Letters|June 6, 2014
Pyrazolopyridine Inhibitors of B-Raf(V600E). Part 1: The Development of Selective, Orally Bioavailable, and Efficacious InhibitorsSteve Wenglowsky, Li Ren, Kateri A Ahrendt, et al.
Biorxiv : the Preprint Server for Biology|February 20, 2025
Temporal and spatial composition of the tumor microenvironment predicts response to immune checkpoint inhibitionNoah F Greenwald, Iris Nederlof, Cameron Sowers, et al.
Nature Cancer|February 18, 2026
Temporal and spatial composition of the tumor microenvironment predicts response to immune checkpoint inhibition in metastatic TNBCNoah F Greenwald, Iris Nederlof, Cameron Sowers, et al.
Cancer Cell|November 18, 2022
Molecular classification and biomarkers of clinical outcome in breast ductal carcinoma in situ: Analysis of TBCRC 038 and RAHBT cohortsSiri H Strand, Belén Rivero-Gutiérrez, Kathleen E Houlahan, et al.
Cancer Cell|July 11, 2023
Molecular classification and biomarkers of clinical outcome in breast ductal carcinoma in situ: Analysis of TBCRC 038 and RAHBT cohortsSiri H Strand, Belén Rivero-Gutiérrez, Kathleen E Houlahan, et al.
Pageof 3

Showing results (21-30 of 30) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 30 results.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 5, 2013
Targeting activated Akt with GDC-0068, a novel selective Akt inhibitor that is efficacious in multiple tumor modelsJie Lin, Deepak Sampath, Michelle A Nannini, et al.
Bioorganic & Medicinal Chemistry Letters|October 26, 2010
Discovery of dihydrothieno- and dihydrofuropyrimidines as potent pan Akt inhibitorsJosef R Bencsik, Dengming Xiao, James F Blake, et al.
Nature Communications|September 21, 2018
Differentiation-state plasticity is a targetable resistance mechanism in basal-like breast cancerTyler Risom, Ellen M Langer, Margaret P Chapman, et al.
Nature Biotechnology|November 19, 2021
Whole-cell segmentation of tissue images with human-level performance using large-scale data annotation and deep learningNoah F Greenwald, Geneva Miller, Erick Moen, et al.
Cell|January 22, 2022
Transition to invasive breast cancer is associated with progressive changes in the structure and composition of tumor stromaTyler Risom, David R Glass, Inna Averbukh, et al.
ACS Medicinal Chemistry Letters|June 6, 2014
Pyrazolopyridine Inhibitors of B-Raf(V600E). Part 1: The Development of Selective, Orally Bioavailable, and Efficacious InhibitorsSteve Wenglowsky, Li Ren, Kateri A Ahrendt, et al.
Biorxiv : the Preprint Server for Biology|February 20, 2025
Temporal and spatial composition of the tumor microenvironment predicts response to immune checkpoint inhibitionNoah F Greenwald, Iris Nederlof, Cameron Sowers, et al.
Nature Cancer|February 18, 2026
Temporal and spatial composition of the tumor microenvironment predicts response to immune checkpoint inhibition in metastatic TNBCNoah F Greenwald, Iris Nederlof, Cameron Sowers, et al.
Cancer Cell|November 18, 2022
Molecular classification and biomarkers of clinical outcome in breast ductal carcinoma in situ: Analysis of TBCRC 038 and RAHBT cohortsSiri H Strand, Belén Rivero-Gutiérrez, Kathleen E Houlahan, et al.
Cancer Cell|July 11, 2023
Molecular classification and biomarkers of clinical outcome in breast ductal carcinoma in situ: Analysis of TBCRC 038 and RAHBT cohortsSiri H Strand, Belén Rivero-Gutiérrez, Kathleen E Houlahan, et al.
Pageof 3